Current Assets
Available-for-Sale Debt Securities - Amortized Cost
Medtronic Available-for-Sale Debt Securities - Amortized Cost increased by 3.0% to $7.26B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 6.5%, from $6.82B to $7.26B. Over 5 years (FY 2020 to FY 2025), Available-for-Sale Debt Securities - Amortized Cost shows a downward trend with a -3.1% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
First reportedQ1 2018
Last reportedQ4 2025Feb 24, 2026
Metric ID:
afs_debt_securities_amortized_costHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.5B | $7.74B | $7.8B | $7.13B | $7.03B | $7.09B | $6.98B | $6.75B | $6.89B | $6.8B | $6.91B | $6.97B | $6.69B | $6.71B | $6.82B | $6.83B | $6.91B | $7.05B | $7.26B |
| QoQ Change | — | +3.3% | +0.7% | -8.5% | -1.4% | +0.9% | -1.6% | -3.3% | +2.1% | -1.3% | +1.7% | +0.8% | -4.0% | +0.3% | +1.6% | +0.2% | +1.2% | +1.9% | +3.0% |
| YoY Change | — | — | — | — | -6.2% | -8.4% | -10.5% | -5.4% | -2.0% | -4.2% | -0.9% | +3.3% | -2.9% | -1.3% | -1.4% | -2.0% | +3.3% | +5.0% | +6.5% |
Range$6.69B – $7.8B
CAGR-0.7%
Avg YoY Growth-1.8%
Median YoY Growth-2.0%
Current Streak6 quarters growth
Available-for-Sale Debt Securities - Amortized Cost at Other Companies
Frequently Asked Questions
- What is Medtronic's available-for-sale debt securities - amortized cost?
- Medtronic (MDT) reported available-for-sale debt securities - amortized cost of $7.26B in Q4 2025.
- How has Medtronic's available-for-sale debt securities - amortized cost changed year-over-year?
- Medtronic's available-for-sale debt securities - amortized cost increased by 6.5% year-over-year, from $6.82B to $7.26B.
- What is the long-term trend for Medtronic's available-for-sale debt securities - amortized cost?
- Over 5 years (2020 to 2025), Medtronic's available-for-sale debt securities - amortized cost has grown at a -3.1% compound annual growth rate (CAGR), from $8.51B to $7.26B.